Marrow Protection Effect of Amifostine in Chemotherapy Patients with Osteosareoma

OBJECTIVE To explore the effect of amifostine on hematological toxicity in chemotherapy patients with osteosareoma.METHODS Forty two patients were divided into treatment group and control group,21 patients in each group.After MTX-MTX-DDP-ADM chemotherapy,the hematological toxicity of chemotherapy was observed.RESULTS After three cycles of chemotherapy,the rate of Ⅳ° neutropenia in treatment group was 28.6%,and 66.7% in control group(P0.05).After four cycles of chemotherapy,the rate of Ⅳ° leukopenia in treatment group was 33.3%,and 81.0% in control group(P0.01).The rate of Ⅳ° neutropenia in treatment group was 33.3%,and 81.0% in control group(P0.01).Compared the average number of red blood cell transfusion with the two group,the number of treatment group was significantly lower than that of control group(P0.01).CONCLUSION After amifostine used in chemotherapy patients with osteosareoma,the rate of Ⅳ° leukopenia and neutropenia,as well as the average number of red blood cell transfusion was reduced.It has no influence on survival rate and it is safe.